浙江华康药业股份有限公司 第六届董事会第三十三次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 一、董事会会议召开情况 浙江华康药业股份有限公司（以下简称"公司"）第六届董事会第三十三次会 议于 2025 年 10 月 28 日以现场与通讯相结合的方式召开，本次会议通知于 2025 年 10 月 22 日以通讯方式向全体董事发出。本次会议应出席董事 9 名，实际出席 董事 9 名。公司董事长陈德水先生主持会议，本次会议的召集、召开符合《公司 法》和《公司章程》的有关规定，会议合法有效。 | 证券代码：605077 | 证券简称：华康股份 | 公告编号：2025-086 | | --- | --- | --- | | 债券代码：111018 | 债券简称：华康转债 | | 本议案已经董事会审计委员会、独立董事专门会议全体成员审议通过，并同 意提交公司董事会审议。 具体内容详见同日披露的《华康股份关于新增 2025 年度日常关联交易预计 的公告》（公告编号 2025-088）。 二、董事会会议审议情况 （三）审 ...

根据中国证券监督管理委员会《关于同意浙江华康药业股份有限公司向不特 定对象发行可转换公司债券注册的批复》（证监许可〔2023〕2739 号），本公司 由主承销商东方证券承销保荐有限公司向不特定对象发行可转换公司债券 13,030,230 张，每张面值为人民币 100.00 元，按面值发行，发行总额为人民币 130,302.30 万元，共计募集资金 130,302.30 万元，扣除本次发行费用 963.77 万元 后，公司本次募集资金净额为 129,338.53 万元。上述募集资金到位情况业经天健 会计师事务所（特殊普通合伙）验证，并由其出具《验资报告》（天健验〔2023〕755 号）。 | 证券代码：605077 | 证券简称：华康股份 | 公告编号：2025-092 | | --- | --- | --- | | 债券代码：111018 | 债券简称：华康转债 | | 浙江华康药业股份有限公司 关于向不特定对象发行可转换公司债券募投项目结项的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示： 浙江华康 ...

东方证券股份有限公司 关于浙江华康药业股份有限公司 2025 年度新增日常关联交易预计的核查意见 东方证券股份有限公司（以下简称"东方证券"或"保荐机构"、 "保荐人"） 作为浙江华康药业股份有限公司（以下简称"华康股份"或"公司"）持续督导工作 的保荐机构，根据《证券发行上市保荐业务管理办法》《上市公司募集资金监管 规则》《上海证券交易所上市公司自律监管指引第 1 号——规范运作》等法律法 规，对华康股份 2025 年度新增日常关联交易预计事项进行了核查，核查情况如 下： 一、新增日常关联交易基本情况 （一）2025 年度日常关联交易的预计和执行情况 公司分别于 2025 年 2 月 26 日和 2025 年 3 月 21 日，召开公司第六届董事会 第二十九次会议和 2024 年年度股东大会，审议通过了《关于确认公司 2024 年度 日常关联交易及 2025 年度日常关联交易预计的议案》，具体内容详见公司于 2025 年 2 月 28 日在上海证券交易所网站（http://www.sse.com.cn）发布的《华康股份 关于确认公司 2024 年度日常关联交易及 2025 年度日常关联交易预计的公告》 （2 ...

Company Overview - Huakang Co., Ltd. (SH 605077) announced on October 28 that its 33rd meeting of the sixth board of directors was held, discussing the election of directors to represent the company in its affairs [1] - As of the report, Huakang's market capitalization is 5.5 billion yuan [1] Financial Performance - For the year 2024, Huakang's revenue composition is as follows: 99.51% from the agricultural and sideline food processing industry, and 0.49% from other businesses [1]

Financial Performance - The company's operating revenue for the third quarter reached ¥1,093,165,350.61, an increase of 46.33% compared to the same period last year[4]. - The total profit for the quarter was ¥42,471,912.19, reflecting a decrease of 10.35% year-over-year[4]. - Net profit attributable to shareholders was ¥34,676,338.94, down 28.55% from the previous year[4]. - The net profit after deducting non-recurring gains and losses was ¥30,681,673.79, a decline of 40.47% year-over-year[4]. - Basic earnings per share for the quarter were ¥0.12, down 29.41% year-over-year[5]. - Total operating revenue for the first three quarters of 2025 reached ¥2,959,027,061.98, a significant increase of 40.6% compared to ¥2,105,806,164.55 in the same period of 2024[20]. - Net profit for the first three quarters of 2025 was ¥170,589,214.44, a decrease of 8.9% from ¥187,389,971.00 in 2024[21]. - Basic earnings per share for the first three quarters of 2025 were ¥0.57, down from ¥0.63 in 2024[22]. Cash Flow - The cash flow from operating activities for the year-to-date period was ¥334,074,436.24, an increase of 307.49% compared to the same period last year[5]. - Operating cash inflow totaled approximately $4.26 billion, an increase from $2.57 billion year-over-year[25]. - Operating cash outflow amounted to about $3.93 billion, compared to $2.49 billion in the previous year[25]. - Net cash flow from operating activities was approximately $334.07 million, up from $81.98 million year-over-year[25]. - Cash inflow from investment activities reached around $815.13 million, compared to $648.88 million in the prior year[25]. - Cash outflow from investment activities was approximately $1.39 billion, down from $2.00 billion year-over-year[25]. - Net cash flow from investment activities was negative at about $573.02 million, an improvement from negative $1.35 billion in the previous year[25]. - Cash inflow from financing activities was approximately $1.40 billion, compared to $348.12 million year-over-year[26]. - Cash outflow from financing activities totaled about $1.24 billion, an increase from $802.87 million in the previous year[26]. - Net cash flow from financing activities was approximately $166.87 million, a turnaround from negative $454.75 million year-over-year[26]. - The ending cash and cash equivalents balance was approximately $319.82 million, down from $408.46 million in the previous year[26]. Assets and Liabilities - Total assets at the end of the quarter amounted to ¥7,761,480,140.55, an increase of 11.00% from the end of the previous year[5]. - The company's total assets reached ¥7,761,480,140.55, up from ¥6,992,028,952.79, indicating an increase of approximately 11%[16]. - The company's total liabilities increased to ¥3,339,640,462.40 from ¥2,840,038,509.92, representing an increase of approximately 17.6%[16]. - The company's total liabilities increased to ¥4,541,080,912.00 in 2025 from ¥3,736,704,991.08 in 2024, reflecting a growth of 21.5%[17]. - The total equity attributable to shareholders decreased to ¥3,206,298,590.97 in 2025 from ¥3,243,431,005.24 in 2024, a decline of 1.1%[17]. Shareholder Information - The company reported a total of 14,510,674 shares held by Fujian Yake Food Co., Ltd., representing 4.79% of total shares[13]. - The top shareholder, Chen Deshui, holds 47,208,121 shares, accounting for 15.58% of the total shares[12]. Operational Insights - The company attributed the revenue growth to the gradual production ramp-up of the new production line in Zhoushan[9]. - The decline in net profit was primarily due to changes in product sales structure and increased financial expenses from convertible bond interest[10]. - Research and development expenses for the first three quarters of 2025 were ¥104,499,707.10, an increase of 11.5% compared to ¥93,932,063.17 in 2024[21]. - Cash received from sales of goods and services in the first three quarters of 2025 was ¥3,477,576,988.51, compared to ¥1,967,705,218.43 in 2024, indicating a growth of 76.7%[24].

华康股份公告，第三季度营收为10.93亿元，同比增长46.33%；净利润为3467.63万元，同比下降 28.55%。前三季度营收为29.59亿元，同比增长40.52%；净利润为1.68亿元，同比下降9.91%。 ...

| 证券代码：605077 | 证券简称：华康股份 | 公告编号：2025-085 | | --- | --- | --- | | 债券代码：111018 | 债券简称：华康转债 | | 浙江华康药业股份有限公司 关于注销首次公开发行股票募集资金专项账户的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 一、首次公开发行股票募集资金基本情况 三、首次公开发行股票募集资金专项账户销户情况 2024 年 5 月 13 日，经公司 2023 年年度股东大会审议通过，公司结合自身经 营情况、公司战略规划梳理及募集资金使用效率等因素，终止募投项目全厂节能 节水减排绿色发展综合升级改造项目，将结余的募集资金 12,963.95 万元及募集 资金账户利息收入 1,527.47 万元用于永久补充流动资金。 经中国证券监督管理委员会《关于核准浙江华康药业股份有限公司首次公开 发行股票的批复》（证监许可[2020]3152 号）核准，并经上海证券交易所同意， 公司首次公开发行人民币普通股 A 股股票 2,914 万股，每股发行价格为人民 ...

Group 1 - The core viewpoint of the news is that Huakang Co., Ltd. has seen a significant increase in its stock price, rising by 5.28% to 18.35 CNY per share, with a total market capitalization of 5.561 billion CNY [1] - Huakang Co., Ltd. specializes in the research, production, and sales of various functional sugar alcohols and starch sugar products, with its main business revenue composition being 54.36% from crystalline sugar alcohol products, 32.46% from liquid sugars and alcohols, and 13.18% from other products [1] - The company is located in Kaifa County, Zhejiang Province, and was established on July 10, 2001, with its listing date on February 9, 2021 [1] Group 2 - From the perspective of fund holdings, one fund under Wan Jia Fund has a significant position in Huakang Co., Ltd., with the Wan Jia Quantitative Tongshun A fund holding 44,000 shares, accounting for 0.98% of the fund's net value, making it the second-largest holding [2] - The Wan Jia Quantitative Tongshun A fund has a total scale of 28.1768 million CNY and has achieved a year-to-date return of 16.29%, ranking 4630 out of 8162 in its category [2] - The fund has a one-year return of 30.77%, ranking 2195 out of 8024, and a cumulative return since inception of 49.82% [2]

Core Viewpoint - The company is entering a production phase for its "1 million tons corn deep processing health food ingredients project," which is expected to impact its revenue and profit structure due to changes in product mix and rising management costs [1] Group 1: Project Updates - The first phase of the "1 million tons corn deep processing health food ingredients project" is entering production, focusing on liquid syrup and some crystalline sugar alcohol products [1] - The second phase of the "200 million tons corn deep processing health food ingredients project" is planned for future development, with various product lines to be constructed at an appropriate time [1] Group 2: Financial Performance - The gross margin has decreased primarily due to changes in the sales product structure caused by the launch of production lines at Zhoushan Huakang [1] - Management expenses are expected to rise in 2024 due to increased employee compensation related to the Zhoushan project and higher stock-based compensation expenses from the company's equity incentive plan [1] Group 3: Growth Drivers - The company's xylitol, crystalline sorbitol, and crystalline maltitol products are leading in market capacity and output, which will continue to be the main sources of revenue and profit [1]

| 证券代码：605077 | 证券简称：华康股份 | 公告编号：2025-084 | | --- | --- | --- | | 债券代码：111018 | 债券简称：华康转债 | | 浙江华康药业股份有限公司 可转债转股结果暨股份变动公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示： 累计转股情况：浙江华康药业股份有限公司（以下简称"公司"）本次 发行的"华康转债"自 2024 年 7 月 1 日起可转换为本公司股份。截至 2025 年 9 月 30 日，累计人民币 804,000 元"华康转债"转换成公司股份，占可转债发行 总量的 0.0617%；转股数量为 47,631 股，占可转债转股前公司发行股份总额 （304,989,880 股）的 0.0156%。 本季度转股情况：自 2025 年 7 月 1 日至 2025 年 9 月 30 日，共有人民币 26,000 元"华康转债"已转换成公司股份，占可转债发行总量的 0.0020%；转股 数量为 1,577 股，占可转债转股前公司发行股份总额（3 ...